Trials / Withdrawn
WithdrawnNCT00319332
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
A Multi-center, Randomized, Phase 3 Study of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen for Patients With Relapsed or Transformed Follicular Non-Hodgkin's Lymphoma
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, randomized, study to compare Iodine I 131 Tositumomab therapeutic regimen to Ibritumomab Tiuxetan therapeutic regimen in the treatment of patients with relapsed or transformed follicular non-Hodgkin's B-cell lymphoma. A total of 350 patients, approximately 175 patients per arm, will be enrolled at 30 to 40 sites in the United States.
Conditions
- Lymphoma, Small Cleaved-Cell, Follicular
- Lymphoma, Large-Cell, Follicular
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ibritumomab Tiuxetan | |
| DRUG | Iodine I 131 Tositumomab |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2021-02-01
- Completion
- 2021-02-01
- First posted
- 2006-04-27
- Last updated
- 2015-04-17
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00319332. Inclusion in this directory is not an endorsement.